Holen Sie sich die Stockscreener-App
48.57
0.16%
0.08
Schlusskurs vom Vortag:
$48.49
Offen:
$48.25
24-Stunden-Volumen:
2.71M
Relative Volume:
0.75
Marktkapitalisierung:
$20.81B
Einnahmen:
$2.38B
Nettoeinkommen (Verlust:
$1.32B
KGV:
27.28
EPS:
1.7806
Netto-Cashflow:
$897.24M
1W Leistung:
+3.47%
1M Leistung:
+2.32%
6M Leistung:
+33.10%
1J Leistung:
+55.27%
1-Tages-Spanne:
$48.21
$49.06
1-Wochen-Bereich:
$46.06
$49.06
52-Wochen-Spanne:
$29.66
$49.06
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
48.57 | 20.81B | 2.38B | 1.32B | 897.24M | 1.7806 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | UBS | Neutral → Buy |
| 2025-09-30 | Eingeleitet | Goldman | Buy |
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Royalty Pharma Plc Hits New 52-Week High at $48.74 - Markets Mojo
Royalty Pharma (NASDAQ:RPRX) CFO Terrance Coyne Sells 34,791 Shares - MarketBeat
Royalty Pharma (RPRX) CFO-linked entities execute planned share sales - Stock Titan
Royalty Pharma, Johnson & Johnson Strike $500M Autoimmune Drug Deal - Yahoo Finance UK
Multiple RPRX Share Disposals by TPC RP Entities (RPRX) - Stock Titan
Pablo Legorreta: Pioneer of Pharmaceutical Royalties, Financial Innovator, and Founder and CEO of Royalty Pharma - bbntimes.com
Zymeworks Appoints Kristin Stafford as Chief Financial Officer - The Manila Times
J. Safra Sarasin Holding AG Purchases Shares of 90,035 Royalty Pharma PLC $RPRX - MarketBeat
Zymeworks Appoints Kristin Stafford as Chief Financial Officer - GlobeNewswire Inc.
Trading the Move, Not the Narrative: (RPRX) Edition - Stock Traders Daily
Royalty Pharma stock hits 52-week high at $47.87 By Investing.com - Investing.com Australia
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighHere's What Happened - MarketBeat
Royalty Pharma (RPRX) director granted 815-share equity award - Stock Titan
Royalty Pharma stock hits 52-week high at $47.87 - Investing.com
Denali Therapeutics scores $200 million shortly after first drug approval - The Business Journals
TD Cowen reiterates Royalty Pharma stock Buy rating on lupus drug potential By Investing.com - Investing.com South Africa
Royalty Pharma and J&J partner to develop autoimmune treatment - Yahoo Finance
Royalty Pharma signs $500M co-development agreement with J&J - MSN
Royalty Pharma in $500M R&D funding collaboration with J&J - MSN
Royalty Pharma commits $500M to J&J autoimmune drug development By Investing.com - in.investing.com
Royalty Pharma commits $500M to J&J autoimmune drug development - Investing.com
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases - Bitget
Johnson & Johnson taps Royalty Pharma for $500M autoimmune drug push - Stock Titan
SG Americas Securities LLC Buys 234,629 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Sold by Cooper Investors PTY Ltd. - MarketBeat
Eastern Bank Acquires 263,867 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Wedge Capital Management L L P NC Lowers Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Wealth Enhancement Advisory Services LLC Buys 165,451 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Refreshes Leadership As AI And Asia Shape Valuation Story - Yahoo Finance
Royalty Pharma PLC (NASDAQ:RPRX) Given Average Rating of "Buy" by Analysts - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Emerges as a Compelling Value Investment - ChartMill
RPRX Stock Price, Quote & Chart | ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) - ChartMill
Morgan Stanley Maintains a Buy Rating on Royalty Pharma Plc (RPRX) With a $55 PT - MSN
RPRX SEC FilingsRoyalty Pharma Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Royalty Pharma EVP Coyne sells shares worth $1.58 million By Investing.com - Investing.com Australia
Insider Selling: Royalty Pharma (NASDAQ:RPRX) CFO Sells 34,791 Shares of Stock - MarketBeat
Royalty Pharma EVP Coyne sells shares worth $1.58 million - Investing.com
Royalty Pharma (RPRX) CFO’s entities sell 34,791 shares under 10b5-1 plan - Stock Titan
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Nordea Investment Management AB Grows Position in Royalty Pharma PLC $RPRX - MarketBeat
How Royalty Pharma’s New AI and Dealmaking Hires Could Shape RPRX’s Royalty Sourcing Strategy - Sahm
Royalty Pharma names Lucas Glass as head of artificial intelligence By Investing.com - Investing.com India
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks - Yahoo Finance UK
Affiliates of RPRX sell multiple blocks of common stock (RPRX) - Stock Titan
Royalty Pharma plc Appoints Lucas Glass as Head of Artificial Intelligence, Effective April 2026 - MarketScreener
Royalty Pharma names Lucas Glass as head of artificial intelligence - Investing.com
Royalty Pharma plc (RPRX) Latest Stock News & Headlines - Yahoo Finance
Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence - The Globe and Mail
How The Royalty Pharma (RPRX) Story Is Shifting With New Deals And Updated Expectations - Yahoo Finance
UBS and Citi are bullish on Royalty Pharma plc (RPRX) – here’s why - MSN
(RPRX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.76%
1.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):